PDCD1 and Miyoshi myopathy: Forty-four grade 3 or 4 adverse events were reported in 34 of the 251 MM and UM patients treated with immunotherapy (26 severe adverse events in 20 patients treated with anti-CTLA-4, and 18 severe adverse events in 14 patients treated with anti-PD1).